Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 23, 2018 - Issue 1
Submit an article Journal homepage
682
Views
3
CrossRef citations to date
0
Altmetric
Review

Emerging treatment options for uterine fibroids

Jacques DonnezCatholic University of Louvain, Société de Recherche pour l’Infertilité (SRI), Brussels, BelgiumCorrespondence[email protected]
View further author information
,
Pablo ArriagadaGedeon Richter/Preglem S.A., Geneva, SwitzerlandView further author information
,
Olivier DonnezInstitut du Sein et de Chirurgie Gynécologique d’Avignon, Polyclinique Urbain V (ELSAN Group), Avignon, FranceView further author information
&
Marie-Madeleine DolmansGynecology Department, Cliniques Universitaires St-Luc, Brussels, Belgium;Pôle de Gynécologie, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, BelgiumView further author information
Pages 17-23 | Received 13 Nov 2017, Accepted 26 Feb 2018, Published online: 12 Mar 2018

References

  • Donnez J, Dolmans MM. Uterine fibroid management: from the present to the future. Hum Reprod Update. 2016;22:665–686.
  • Kim J, Sefton EC. The role of progesterone signaling in the pathogenesis of uterine leiomyoma. Mol Cell Endocrinol. 2012;358:223–231.
  • Stewart EA, Nicholson WK, Bradley L, et al. The burden of uterine fibroids for African-American women: results of a national survey. J Womens Health (Larch-Rnt). 2013;22:807–816.
  • Stewart EA. Clinical practice. Uterine fibroids. N Engl J Med. 2015;372(17):1646–1655.
  • Lumsden MA, Hamoodi I, Gupta J, et al. Fibroids: diagnosis and management. Bmj. 2015 Oct 13;351:h4887.
  • Wise LA, Laughlin-Tommaso SK. Epidemiology of uterine fibroids: from menarche to menopause. Clin Obstet Gynecol. 2016;59:2–24.
  • Petraglia F, Serour GI, Chapron C. The changing prevalence of infertility. Int J Gynaecol Obstet. 2013;123(Suppl 2):S4–8.
  • IMS data August 2017. Available from: www.IQVIA.com.
  • Nisolle M, Gillerot S, Casanas-Roux F, et al. Immunohistochemical study of the proliferation index, oestrogen receptors and progesterone receptors A and B in leiomyomata and normal myometrium during the menstrual cycle and under gonadotrophin-releasing hormone agonist therapy. Hum Reprod. 1999;14:2844–2850.
  • Bouchard P, Chabbert-Buffet N, Fauser BC. Selective progesterone receptor modulators in reproductive medicine; pharmacology, clinical efficacy and safety. Fertil Steril. 2011;96:1175–1189.
  • Chabbert-Buffet EN, Bouchard P. Fibroid growth and medical options for treatment. Fertil Steril. 2014;102:630–639.
  • Bestel E, Donnez J. The potential of selective progesterone receptor modulators for the treatment of uterine fibroids. Expert Rev Endocrinol Metab. 2014;9:79–92.
  • Donnez J, Vázquez F, Tomaszewski J, et al. PEARL III and PEARL III Extension Study Group. Long-term treatment of uterine fibroids with ulipristal acetate. Fertil Steril. 2014;101:1565–1573.
  • Donnez J, Tatarchuk TF, Bouchard P, et al. PEARL I Study Group. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012;366:409–420.
  • Courtoy G, Donnez J, Marbaix E, et al. In vivo mechanisms of uterine myoma volume reduction with ulipristal acetate treatment. Fertil Steril. 2015;104:426–434.
  • Courtoy G, Donnez J, Ambroise J, et al. Gene expression changes in the response of uterine myomas to ulipristal acetate treatment. Reprod Biomed Online. 2018. In revision.
  • Courtoy G, Henriet P, Marbaix E, et al. Matrix metalloproteinase activity correlates with uterine myoma volume reduction after ulipristal acetate treatment. J Clin Endocrinol Metabolism. 2018 [Epub ahead of print].
  • Mehine EK, Heinonen HR, Mäkinen N, et al. Integrated data analysis reveals uterine leiomyoma subtypes with distinct driver pathways and biomarkers. Proc Natl Acad Sci. 2016;113:1315–1320.
  • Williams AR, Bergeron C, Barlox DH, et al. Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. Int J Gynecol Pathol. 2012;31:556–569.
  • Donnez J, Donnez O, Matule D, et al. Long-term medical management of uterine fibroids with ulipristal acetate. Fertil Steril. 2016;105:165–173.
  • Donnez J, Tomaszewski J, Vázquez F, et al. PEARL II Study Group. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med. 2012;366:421–432.
  • Auritec pharm. Available from: http://www.auritecpharma.com/pipeline/
  • Fauser BC, Donnez J, Bouchard P, et al. Safety after extended repeated use of ulipristal acetate for uterine fibroids. PLoS One. 2017;12:e0173523.
  • Munro MG, Critchley HO, Broder MS, et al. FIGO Working Group on Menstrual Disorders. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet. 2011;113:1–2.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.